CtDNA-guided de-escalation of adjuvant chemotherapy in stage III colon cancer: early model-based evaluation of cost-effectiveness
CtDNA-gesteuerte Deeskalation der adjuvanten Chemotherapie bei Kolonkarzinom Stadium III: frühe modellbasierte Bewertung der Kosteneffektivität
Therapeutic Advances in Medical Oncology · 2025-09 · 17
DOI: 10.1177/17588359251384238 ↗Auf einen Blick
Ein Entscheidungsmodell bewertete ctDNA-gesteuerte Deeskalation der adjuvanten Chemotherapie bei Stadium-III-Kolonkarzinom. Gegenüber „All ACT“ war die Strategie derzeit nicht kosteneffektiv.
Fragestellung
Ist eine ctDNA-gesteuerte Deeskalation der adjuvanten Chemotherapie bei Stadium-III-Kolonkarzinom kosteneffektiv?
Methode
Entscheidungsmodell „PATTERN-stageIII“ für chirurgisch behandelte Stadium-III-Patient:innen; Vergleich von „All ACT“ mit 3 Deeskalationsstrategien; Kosten, QALYs und net monetary benefit wurden geschätzt.
Ergebnisse
Bei Strategie 1, 2 und 3 sollten 52 %, 61 % und 88 % ACT erhalten; der QALY-Verlust pro Person betrug 0,322, 0,237 bzw. 0,034. „All ACT“ war in der Kosteneffektivität bevorzugt.
Einschränkungen
Modellbasierte Frühbewertung; Sensitivitätsanalysen zeigten nur unter bestimmten Annahmen Kosteneffektivität.
Schlussfolgerung der Autor:innen
ctDNA-gesteuerte Strategien zur Deeskalation der adjuvanten Chemotherapie sind derzeit gegenüber „All ACT“ nicht kosteneffektiv.
Kernaussagen
- 52 %, 61 % und 88 % der Patient:innen würden ACT erhalten
- QALY-Verlust pro Person: 0,322; 0,237; 0,034
- Nicht kosteneffektiv gegenüber „All ACT“
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Fachartikel in der Zeitschrift Therapeutic Advances in Medical Oncology, online erschienen am 06.11.2025. Verfasst von Haoyue Wang und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology and Data Science, Amsterdam UMC, Amsterdam, The Netherlands. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Maarten van der Weijden foundation, KWF Kankerbestrijding, Health~Holland.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
All stage III colon cancer (CC) patients are recommended adjuvant chemotherapy (ACT) after surgery, while over half are already cured by surgery alone. The prognostic biomarker circulating tumor DNA (ctDNA) could potentially guide the decision on whom to withhold ACT.
Objective
We assessed the cost-effectiveness of ctDNA-guided ACT de-escalation in stage III CC.
Design
A decision model “PATTERN-stageIII” simulates CC from diagnosis till death in surgically treated stage III patients.
Methods
We evaluated administering ACT in all patients (i.e., All ACT strategy), and three ACT de-escalation strategies by omitting ACT in patients who are (Strategy 1) both pT1-3N1 and ctDNA-negative, (Strategy 2) pT1-3N1, have no vascular invasion, and are ctDNA-negative, and (Strategy 3) pT1-2N1 and ctDNA-negative. For each strategy, costs, quality-adjusted life years (QALYs), and net monetary benefit were estimated. Sensitivity analyses assessed changes in ACT effectiveness and ctDNA-related parameters.
Results
In de-escalation strategies 1, 2, and 3, respectively, 52%, 61%, and 88% of patients were predicted to receive ACT, thereby losing 0.322, 0.237, and 0.034 QALYs per person. The “All ACT strategy” was preferred in terms of cost-effectiveness. Sensitivity analyses demonstrated scenarios where ctDNA-guided de-escalation strategies were cost-effective compared to “All ACT,” including improved ACT treatment effect in ctDNA-positive patients, higher ctDNA positivity rates, enhanced ctDNA prognostic value, and/or reduced ctDNA testing costs. Conclusion: ctDNA-guided strategies for ACT de-escalation are currently not cost-effective compared to an “All ACT strategy.” One explanation is the non-negligible recurrence risk in ctDNA-negative patients. ctDNA-guided strategies could potentially become cost-effective if more than two ctDNA-related parameters improve simultaneously.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Epidemiology and Data Science, Amsterdam UMC, Amsterdam, The Netherlands.
- Amsterdam Public Health Research Institute, Methodology Program, Amsterdam, The Netherlands.
- Department of Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
- Department of Surgical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
- Department of Laboratory Medicine, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
- Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
ORCID-Profile: Haoyue Wang, Astrid Kramer, Marjolein J E Greuter, Birgit Lissenberg-Witte, Gerrit A Meijer, Niels F M Kok, Daan van den Broek, Geraldine R Vink, Mark Sausen, Remond J A Fijneman, Veerle M H Coupé
Förderung
- Maarten van der Weijden foundation
- KWF Kankerbestrijding
- Health~Holland
- KWF/SU2C-DCS International Translational Cancer Research Dream Team Grant
- Sacha Swarttouw-Hijmans foundation
- Commonwealth Foundation
- National Institutes of Health
- Dr. Miriam and Sheldon G. Adelson Medical Research Foundation
Zitieren
APA
Wang, H., Kramer, A., Greuter, M. J. E., Rubio-Alarcón, C., Lissenberg-Witte, B., Meijer, G. A., Kok, N. F. M., van den Broek, D., Vink, G. R., Roodhart, J. M. L., Sausen, M., Fijneman, R. J. A., & Coupé, V. M. H. (2025). CtDNA-guided de-escalation of adjuvant chemotherapy in stage III colon cancer: early model-based evaluation of cost-effectiveness. Therapeutic Advances in Medical Oncology, 17. https://doi.org/10.1177/17588359251384238
Vancouver
Wang H, Kramer A, Greuter MJE, Rubio-Alarcón C, Lissenberg-Witte B, Meijer GA, et al. CtDNA-guided de-escalation of adjuvant chemotherapy in stage III colon cancer: early model-based evaluation of cost-effectiveness. Therapeutic Advances in Medical Oncology. 2025;17. doi:10.1177/17588359251384238
BibTeX
@article{Wang2025,
author = {Wang, Haoyue and Kramer, Astrid and Greuter, Marjolein J E and Rubio-Alarcón, Carmen and Lissenberg-Witte, Birgit and Meijer, Gerrit A and Kok, Niels F M and van den Broek, Daan and Vink, Geraldine R and Roodhart, Jeanine M L and Sausen, Mark and Fijneman, Remond J A and Coupé, Veerle M H},
title = {CtDNA-guided de-escalation of adjuvant chemotherapy in stage III colon cancer: early model-based evaluation of cost-effectiveness},
journal = {Therapeutic Advances in Medical Oncology},
year = {2025},
volume = {17},
doi = {10.1177/17588359251384238}
}
EUVIMED